http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0293395-A4
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fa8b1586bbcf805bfe716d8ab80acaf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0bae7d244c566c2e80b002f82a27d7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dce944e69993ebb4cb4fbdb9311043e8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-827 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57469 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 1987-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00630d1a5db280677c13ab3a99ae3130 |
| publicationDate | 1988-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0293395-A4 |
| titleOfInvention | CANCER SCREENING TEST. |
| abstract | The disialyted disaccharide beta-D-Gal(1->3)-D-GalNAc, which specifically binds with peanut agglutinin (PNA) or is oxidized by galactose oxidase, has been discovered in the body fluids of patients with cancer and precancer. Because of the presence of beta-D-Gal-(1->3)-D-GalNAc also on neuraminidase-treated erythrocytes of the ABO type, their competitive binding with PNA has been exploited to develop a hemagglutination inhibition assay. Additional methods of simple detection of this disaccharide include a latex agglutination test, enzyme-avidin-biotinylated PNA, immunochemical detection of the disaccharide, and a galactose oxidase strip test. This rapid, simple and inexpensive assay is designed to test the presence of beta-D-Gal-(1->3)-D-GalNAc the body fluids and has the potential for screening populations for cancer and precancer. |
| priorityDate | 1986-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 239.